Kunihiko Iizuka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kunihiko Iizuka has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Akihiro Yoshii
The First Department of Internal Medicine, Gunma University School of Medicine
5 shared publicationsTsugio Nakazawa
Faculty of Health Sciences, Gunma University School of Medicine
5 shared publicationsKunio Dobashi
11First Department of Internal Medicine, Gunma University Faculty of Medicine, School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan
3 shared publicationsMasatomo Mori
11First Department of Internal Medicine, Gunma University Faculty of Medicine, School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan
3 shared publicationsTakeo Horie
3 shared publications- Masatomo Mori
First Department of Internal Medicine, Gunma University School of Medicine
2 shared publications
Latest Publications
- 1 January 2002
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 41 (10) , 798-804
Effects of Fluticasone Propionate on Bone Mineral Density in Patients with Persistent Bronchial Asthma.
Objective To evaluate osteoporosis in asthmatic patients. Methods Bone mineral density (BMD) was measured using three different methods, namely computed X-ray densitometry (CXD), digital image processing (DIP), and dual energy X-ray absorptiometry (DXA). The BMD data were standardized using the sex- and age-matched mean value of BMD. Patients One hundred and twenty-eight patients with persistent asthma. Results The standardized BMD expressed as Z-score in asthmatic patients was significantly lower than the norm (Z-score -0.48±1.17, mean±SD). In patients who had been continuously treated with oral corticosteroids (OCS), the standardized BMD was significantly lower than that in patients treated without OCS. In addition, the standardized BMD in patients 60 years and over (Z-score -0.71±1.10, mean±SD, n=58) had decreased to a greater extent than the decrease seen in patients under 60 years (Z-score -0.30±1.21, n=70). Moreover, BMD in these older patients decreased after a 6- month treatment protocol involving the use of an inhaled corticosteroid, fluticasone propionate (FP). During the 6 months, the treatment did not affect BMD in patients who were receiving FP for the first time. Although the BMD did not decrease in patients treated with FP without OCS, the BMD in patients treated with both FP and OCS decreased during the 6 months. Conclusion These results indicate that the continuous administration of OCS in patients with severe persistent asthma, particularly in older patients, may affect BMD in the short term even at a low OCS dose. (Internal Medicine 41: 798-804, 2002)
- 1 January 2002
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 41 (10) , 798-804
Effects of Fluticasone Propionate on Bone Mineral Density in Patients with Persistent Bronchial Asthma.
Objective To evaluate osteoporosis in asthmatic patients. Methods Bone mineral density (BMD) was measured using three different methods, namely computed X-ray densitometry (CXD), digital image processing (DIP), and dual energy X-ray absorptiometry (DXA). The BMD data were standardized using the sex- and age-matched mean value of BMD. Patients One hundred and twenty-eight patients with persistent asthma. Results The standardized BMD expressed as Z-score in asthmatic patients was significantly lower than the norm (Z-score -0.48±1.17, mean±SD). In patients who had been continuously treated with oral corticosteroids (OCS), the standardized BMD was significantly lower than that in patients treated without OCS. In addition, the standardized BMD in patients 60 years and over (Z-score -0.71±1.10, mean±SD, n=58) had decreased to a greater extent than the decrease seen in patients under 60 years (Z-score -0.30±1.21, n=70). Moreover, BMD in these older patients decreased after a 6- month treatment protocol involving the use of an inhaled corticosteroid, fluticasone propionate (FP). During the 6 months, the treatment did not affect BMD in patients who were receiving FP for the first time. Although the BMD did not decrease in patients treated with FP without OCS, the BMD in patients treated with both FP and OCS decreased during the 6 months. Conclusion These results indicate that the continuous administration of OCS in patients with severe persistent asthma, particularly in older patients, may affect BMD in the short term even at a low OCS dose. (Internal Medicine 41: 798-804, 2002)
- 1 October 1999
- Published by Wiley in British Journal of Pharmacology
- Vol. 128 (4) , 925-933
A major role for the Rho‐associated coiled coil forming protein kinase in G‐protein‐mediated Ca2+ sensitization through inhibition of myosin phosphatase in rabbit trachea
G protein‐mediated Ca2+ sensitization of airway smooth muscle contraction was investigated with respect to the relative importance of Rho‐associated coiled coil forming protein kinase (ROCK) and protein kinase C (PKC). We examined the effects of Y‐27632, a ROCK inhibitor, and GF 109203X, a PKC inhibitor, on guanosine 5′‐O‐(3‐thiotriphosphate) (GTPγS)‐induced contraction in α‐toxin‐ or β‐escin‐permeabilized rabbit trachea. Although pre‐treatment with Y‐27632 dose‐dependently inhibited GTPγS (10 μM)‐induced Ca2+ sensitization of α‐toxin‐permeabilized trachea, a Y‐27632‐insensitive component (approximately 16% of the maximum contraction) was retained during the early phase of the GTPγS response in the presence of Y‐27632 (100 μM). GF 109203X (5 μM) abolished 1 μM 4β‐phorbol 12, 13‐dibutyrate (PDBu)‐induced, but only partially inhibited the GTPγS‐induced Ca2+ sensitization. A combination of Y‐27632 (100 μM) and GF 109203X (5 μM) totally abolished the GTPγS response. GTPγS caused only a small contraction in the absence of Ca2+. Wortmannin (30 μM), a myosin light chain kinase (MLCK) inhibitor, completely inhibited Ca2+‐induced contraction. ATP‐triggered contraction of the strip which had been treated with calyculin A (1 μM), a phosphatase inhibitor, in rigor solutions was markedly slowed by worthmannin (30 μM), but not by Y‐27632 (100 μM), in the presence of GTPγS and Ca2+. GTPγS, but not PDBu, contracted the β‐escin‐permeabilized trachea in the absence of Ca2+, but the presence of Ca2+‐independent MLCK. We conclude that ROCK plays a primary role in G‐protein‐mediated Ca2+ sensitization, which requires MLCK activity, with minor contribution of PKC to the early phase of contraction, and PDBu utilizes conventional PKC(s) in airway smooth muscle. British Journal of Pharmacology (1999) 128, 925–933; doi:10.1038/sj.bjp.0702864
- 1 October 1999
- Published by Wiley in British Journal of Pharmacology
- Vol. 128 (4) , 925-933
A major role for the Rho‐associated coiled coil forming protein kinase in G‐protein‐mediated Ca2+ sensitization through inhibition of myosin phosphatase in rabbit trachea
G protein‐mediated Ca2+ sensitization of airway smooth muscle contraction was investigated with respect to the relative importance of Rho‐associated coiled coil forming protein kinase (ROCK) and protein kinase C (PKC). We examined the effects of Y‐27632, a ROCK inhibitor, and GF 109203X, a PKC inhibitor, on guanosine 5′‐O‐(3‐thiotriphosphate) (GTPγS)‐induced contraction in α‐toxin‐ or β‐escin‐permeabilized rabbit trachea. Although pre‐treatment with Y‐27632 dose‐dependently inhibited GTPγS (10 μM)‐induced Ca2+ sensitization of α‐toxin‐permeabilized trachea, a Y‐27632‐insensitive component (approximately 16% of the maximum contraction) was retained during the early phase of the GTPγS response in the presence of Y‐27632 (100 μM). GF 109203X (5 μM) abolished 1 μM 4β‐phorbol 12, 13‐dibutyrate (PDBu)‐induced, but only partially inhibited the GTPγS‐induced Ca2+ sensitization. A combination of Y‐27632 (100 μM) and GF 109203X (5 μM) totally abolished the GTPγS response. GTPγS caused only a small contraction in the absence of Ca2+. Wortmannin (30 μM), a myosin light chain kinase (MLCK) inhibitor, completely inhibited Ca2+‐induced contraction. ATP‐triggered contraction of the strip which had been treated with calyculin A (1 μM), a phosphatase inhibitor, in rigor solutions was markedly slowed by worthmannin (30 μM), but not by Y‐27632 (100 μM), in the presence of GTPγS and Ca2+. GTPγS, but not PDBu, contracted the β‐escin‐permeabilized trachea in the absence of Ca2+, but the presence of Ca2+‐independent MLCK. We conclude that ROCK plays a primary role in G‐protein‐mediated Ca2+ sensitization, which requires MLCK activity, with minor contribution of PKC to the early phase of contraction, and PDBu utilizes conventional PKC(s) in airway smooth muscle. British Journal of Pharmacology (1999) 128, 925–933; doi:10.1038/sj.bjp.0702864
- 1 January 1999
- Published by Taylor & Francis in Journal of Asthma
- Vol. 36 (7) , 619-626
Effect of β-Agonists on Production of Cytokines by Activated T Cells Obtained from Asthmatic Patients and Normal Subjects
Intracellular levels of cAMP were found to regulate T cell activity. We examined whether beta2-agonists altered cytokine production and cyclic adenosine monophosphate (cAMP) accumulation in concanavalin A (ConA)-activated peripheral T cells from asthmatic patients. Procaterol and isoproterenol weakly decreased the ConA-elicited interleukin (IL)-4 and IL-5 secretion; however, the inhibitory effect of procaterol on the ConA-induced IL-2 secretion was inferior to that of isoproterenol in normal controls and was little in asthmatics. The intracellular accumulation of cAMP by procaterol was not altered compared with that by isoproterenol. Results suggest that there is a qualitative difference between procaterol- and isoproterenol-induced cAMP accumulation in T cells.
- 1 January 1999
- Published by Taylor & Francis in Journal of Asthma
- Vol. 36 (7) , 619-626
Effect of β-Agonists on Production of Cytokines by Activated T Cells Obtained from Asthmatic Patients and Normal Subjects
Intracellular levels of cAMP were found to regulate T cell activity. We examined whether beta2-agonists altered cytokine production and cyclic adenosine monophosphate (cAMP) accumulation in concanavalin A (ConA)-activated peripheral T cells from asthmatic patients. Procaterol and isoproterenol weakly decreased the ConA-elicited interleukin (IL)-4 and IL-5 secretion; however, the inhibitory effect of procaterol on the ConA-induced IL-2 secretion was inferior to that of isoproterenol in normal controls and was little in asthmatics. The intracellular accumulation of cAMP by procaterol was not altered compared with that by isoproterenol. Results suggest that there is a qualitative difference between procaterol- and isoproterenol-induced cAMP accumulation in T cells.
- Open Access
- 22 September 1998
- Published by Wiley in The Journal of Physiology
- Vol. 511 (3) , 915-933
InsP3, but not novel Ca2+ releasers, contributes to agonist‐initiated contraction in rabbit airway smooth muscle
To examine the contributions of the putative Ca2+ releasers, inositol 1,4,5‐trisphosphate (InsP3), cyclic ADP ribose (cADPR), and nicotinate adenine dinucleotide phosphate (NAADP), to carbachol (CCh)‐induced contraction in airway smooth muscle, we measured force development of permeabilized rabbit tracheal smooth muscle, human bronchial smooth muscle and guinea‐pig ileum longitudinal smooth muscle. In the presence of 50 μm GTP, CCh and InsP3 contracted α‐toxin‐permeabilized tracheal smooth muscle dose dependently; the EC50 values for CCh and InsP3 were 1.84 μm and 363 μm, and the maximum responses (normalized to the 30 mM caffeine response) to 100 μm CCh and to 800 μm InsP3 were 206 ± 13.4 % (mean ± s.e.m.) and 84.4 ± 5.3 %, respectively. However, cADPR (10‐300 μm), β‐NAD+ (2.5 mM), FK506 (30 μm) and NAADP (100 μm) neither contracted the strip by themselves nor affected the subsequent CCh (1 μm) response. α‐Toxin‐permeabilized bronchial smooth muscle and ileum smooth muscle also responded to caffeine, InsP3 and CCh but not to cADPR. Both 100 μm 8‐amino‐cADPR, a selective cADPR antagonist, and 100 μm thionicotinamide‐NADP, a selective NAADP antagonist, failed to inhibit the CCh response, although procaine abolished the caffeine, InsP3 and CCh responses in the permeabilized tracheal smooth muscle. Although inhibition of the caffeine response by 30 μm ryanodine was nearly complete, approximately 30 % of the InsP3 (300 μm) plus GTP (50 μm) response was retained, and the resultant response disappeared after the caffeine response was evoked in the presence of ryanodine. Heparin (300 μg ml−1) blocked InsP3 (300 μm) and CCh (3 μm) responses in β‐escin‐permeabilized tracheal smooth muscle, while Ruthenium Red (100 μm) partially inhibited the CCh response. Collectively, InsP3 but not cADPR or NAADP plays a key role in CCh‐initiated contraction, and InsP3 utilizes a single compartment of the caffeine/ryanodine‐sensitive stored Ca2+ in airway smooth muscle.
- 22 September 1998
- Published by Wiley in The Journal of Physiology
- Vol. 511 (3) , 915-933
Open AccessInsP3, but not novel Ca2+ releasers, contributes to agonist‐initiated contraction in rabbit airway smooth muscle
To examine the contributions of the putative Ca2+ releasers, inositol 1,4,5‐trisphosphate (InsP3), cyclic ADP ribose (cADPR), and nicotinate adenine dinucleotide phosphate (NAADP), to carbachol (CCh)‐induced contraction in airway smooth muscle, we measured force development of permeabilized rabbit tracheal smooth muscle, human bronchial smooth muscle and guinea‐pig ileum longitudinal smooth muscle. In the presence of 50 μm GTP, CCh and InsP3 contracted α‐toxin‐permeabilized tracheal smooth muscle dose dependently; the EC50 values for CCh and InsP3 were 1.84 μm and 363 μm, and the maximum responses (normalized to the 30 mM caffeine response) to 100 μm CCh and to 800 μm InsP3 were 206 ± 13.4 % (mean ± s.e.m.) and 84.4 ± 5.3 %, respectively. However, cADPR (10‐300 μm), β‐NAD+ (2.5 mM), FK506 (30 μm) and NAADP (100 μm) neither contracted the strip by themselves nor affected the subsequent CCh (1 μm) response. α‐Toxin‐permeabilized bronchial smooth muscle and ileum smooth muscle also responded to caffeine, InsP3 and CCh but not to cADPR. Both 100 μm 8‐amino‐cADPR, a selective cADPR antagonist, and 100 μm thionicotinamide‐NADP, a selective NAADP antagonist, failed to inhibit the CCh response, although procaine abolished the caffeine, InsP3 and CCh responses in the permeabilized tracheal smooth muscle. Although inhibition of the caffeine response by 30 μm ryanodine was nearly complete, approximately 30 % of the InsP3 (300 μm) plus GTP (50 μm) response was retained, and the resultant response disappeared after the caffeine response was evoked in the presence of ryanodine. Heparin (300 μg ml−1) blocked InsP3 (300 μm) and CCh (3 μm) responses in β‐escin‐permeabilized tracheal smooth muscle, while Ruthenium Red (100 μm) partially inhibited the CCh response. Collectively, InsP3 but not cADPR or NAADP plays a key role in CCh‐initiated contraction, and InsP3 utilizes a single compartment of the caffeine/ryanodine‐sensitive stored Ca2+ in airway smooth muscle.
- 1 July 1997
- Published by Elsevier in Cell Calcium
- Vol. 22 (1) , 21-30
Receptor-dependent G protein-mediated Ca2+ sensitization in canine airway smooth muscle
- 1 July 1997
- Published by Elsevier in Cell Calcium
- Vol. 22 (1) , 21-30
Receptor-dependent G protein-mediated Ca2+ sensitization in canine airway smooth muscle